Language
Open app

Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol ( OATD-01 Development Program )

Molecure's Phase II KITE trial for OATD-01 in pulmonary sarcoidosis will continue without protocol changes following a positive IDMC review.

Why it matters

Attributed market update with source link for portfolio context.

Sources

Attributed news only. Not investment advice.

Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol ( OATD-01 Development Program ) | TahmVest News · TahmVest